COVID-19 antiviral therapy for non-hospitalized immunosuppressed patients with rheumatic diseases is feasible with positive outcomes

Rheumatology (Oxford). 2023 Jun 1;62(6):e185-e187. doi: 10.1093/rheumatology/keac705.

Authors

Chung M A Lin¹, Josh Bennett¹, Lavanya Rajagopala², Ewan Hunter³, Alice R Lorenzi², Bridget Griffiths², Kenneth F Baker^{1

2}

Affiliations

¹ Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
² Musculoskeletal Unit, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
³ Department of Infectious Diseases, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antirheumatic Agents* / therapeutic use
Antiviral Agents / therapeutic use
COVID-19*
Humans
Rheumatic Diseases* / drug therapy

Substances

Antirheumatic Agents
Antiviral Agents